HUP0401535A3 - Somatostatin antagonists and their use - Google Patents

Somatostatin antagonists and their use

Info

Publication number
HUP0401535A3
HUP0401535A3 HU0401535A HUP0401535A HUP0401535A3 HU P0401535 A3 HUP0401535 A3 HU P0401535A3 HU 0401535 A HU0401535 A HU 0401535A HU P0401535 A HUP0401535 A HU P0401535A HU P0401535 A3 HUP0401535 A3 HU P0401535A3
Authority
HU
Hungary
Prior art keywords
somatostatin antagonists
somatostatin
antagonists
Prior art date
Application number
HU0401535A
Other languages
English (en)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of HUP0401535A2 publication Critical patent/HUP0401535A2/hu
Publication of HUP0401535A3 publication Critical patent/HUP0401535A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
HU0401535A 2001-03-08 2002-03-05 Somatostatin antagonists and their use HUP0401535A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08
PCT/US2002/006676 WO2002072602A2 (en) 2001-03-08 2002-03-05 Somatostatin antagonists

Publications (2)

Publication Number Publication Date
HUP0401535A2 HUP0401535A2 (hu) 2004-12-28
HUP0401535A3 true HUP0401535A3 (en) 2009-07-28

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401535A HUP0401535A3 (en) 2001-03-08 2002-03-05 Somatostatin antagonists and their use

Country Status (16)

Country Link
US (3) US7378488B2 (hu)
EP (1) EP1372688B1 (hu)
JP (3) JP4204322B2 (hu)
AR (1) AR035942A1 (hu)
AT (1) ATE394114T1 (hu)
AU (1) AU2002258465B2 (hu)
CA (1) CA2439498A1 (hu)
CZ (1) CZ299362B6 (hu)
DE (1) DE60226419D1 (hu)
DK (1) DK1372688T3 (hu)
ES (1) ES2306766T3 (hu)
HU (1) HUP0401535A3 (hu)
NO (1) NO20033911L (hu)
PL (1) PL362838A1 (hu)
RU (2) RU2263678C2 (hu)
WO (1) WO2002072602A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241737B2 (en) * 2000-10-20 2007-07-10 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Urotensin-II agonists and antagonists
HUP0401535A3 (en) 2001-03-08 2009-07-28 Univ Tulane Somatostatin antagonists and their use
MXPA03009048A (es) * 2001-04-09 2004-02-12 Univ Tulane Agonistas de la somatostatina.
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US8017575B2 (en) * 2004-12-15 2011-09-13 Wilfred Wayne Lautt Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
EP2076535B1 (en) 2006-10-16 2013-03-06 The Salk Institute For Biological Studies Receptor(sstr2)-selective somatostatin antagonists
EP2168983A1 (fr) * 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
EP2351848B1 (en) * 2008-10-29 2018-02-28 Kaneka Corporation Method for producing l-amino acid
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
CA3013882A1 (en) * 2016-02-09 2017-08-17 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE43335T1 (de) * 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク　エンド　カムパニー　インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0278158A3 (en) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin inhibitors containing phenylalanyl-histidine replacements
EP0273696A2 (en) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
CH679045A5 (hu) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (hu) 1987-08-10 1989-02-15
EP0328090A3 (en) 1988-02-10 1990-08-16 Abbott Laboratories Lhrh analogs
EP0457888B1 (en) * 1989-12-08 1996-07-10 The Administrators of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
EP1288223B1 (en) * 1993-08-09 2004-12-08 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutic peptide derivatives
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
EP0956296B1 (en) 1996-12-04 2006-06-21 Societe De Conseils De Recherches Et D'applications Scientifiques (Scras) S.A.S Somatostatin antagonists
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4294959B2 (ja) * 2001-03-06 2009-07-15 ウニベルシタ・デグリ・ストゥッディ・ディ・フェラーラ 髄様甲状腺癌の増殖を変調させる方法
HUP0401535A3 (en) 2001-03-08 2009-07-28 Univ Tulane Somatostatin antagonists and their use
MXPA03009048A (es) 2001-04-09 2004-02-12 Univ Tulane Agonistas de la somatostatina.

Also Published As

Publication number Publication date
WO2002072602A2 (en) 2002-09-19
US20080171853A1 (en) 2008-07-17
NO20033911L (no) 2003-10-29
US20080020970A1 (en) 2008-01-24
DE60226419D1 (de) 2008-06-19
ATE394114T1 (de) 2008-05-15
EP1372688B1 (en) 2008-05-07
EP1372688A2 (en) 2004-01-02
CZ20032281A3 (cs) 2004-01-14
CA2439498A1 (en) 2002-09-19
HUP0401535A2 (hu) 2004-12-28
US7408024B2 (en) 2008-08-05
JP4204322B2 (ja) 2009-01-07
JP2006342171A (ja) 2006-12-21
PL362838A1 (en) 2004-11-02
US20040181032A1 (en) 2004-09-16
CZ299362B6 (cs) 2008-07-02
AU2002258465B2 (en) 2006-01-19
US7378488B2 (en) 2008-05-27
RU2263678C2 (ru) 2005-11-10
AR035942A1 (es) 2004-07-28
JP2004532824A (ja) 2004-10-28
EP1372688A4 (en) 2006-06-14
RU2003129807A (ru) 2005-03-20
RU2005117614A (ru) 2006-11-20
WO2002072602A3 (en) 2003-03-20
ES2306766T3 (es) 2008-11-16
NO20033911D0 (no) 2003-09-04
JP2008255120A (ja) 2008-10-23
RU2328504C2 (ru) 2008-07-10
DK1372688T3 (da) 2008-08-25

Similar Documents

Publication Publication Date Title
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
EP1539941A4 (en) ADZYMES AND THEIR USES
HUP0500989A2 (en) Animicrobial polypeptides and their uses
IL165841A0 (en) Mchir antagonists
HUP0401756A3 (en) Substituted benzimidazole compounds and their use
IL154553A0 (en) Urocortin-iii and uses thereof
GB0220214D0 (en) Compounds and their use
AU2003296369A8 (en) Imminoamines and preparation thereof
HUP0401535A3 (en) Somatostatin antagonists and their use
IL159872A0 (en) Gmg-2 polypeptides and their use
GB0126889D0 (en) Compounds and their uses
AU2003231827A8 (en) Pseudo-tissues and uses thereof
PL363290A1 (en) 1k-polyurethane lacquer and use thereof
GB0227906D0 (en) Compounds and their use
EP1367123A4 (en) NEUROTONIN AND ITS USE
AU2003300396A8 (en) Chemokine antagonists and uses thereof
GB0230134D0 (en) Compounds and their use
GB0106031D0 (en) Use
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
GB0218031D0 (en) Compounds and their use
GB0230281D0 (en) Compounds and their use
AU2003216442A8 (en) Enkurin and uses thereof
GB0124346D0 (en) Receptor and its use
GB0220215D0 (en) Compounds and their use
GB0120084D0 (en) Polypeptides and their uses

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished